Journal of Gastrointestinal Infections

Register      Login

VOLUME 6 , ISSUE 1 ( 2016 ) > List of Articles


Non-antibiotic management for Clostridium difficile infection

Anshul Sood, Chetana Vaishnavi

Keywords : Bacteriotherapy, immunoglobulin therapy, photodynamic therapy

Citation Information : Sood A, Vaishnavi C. Non-antibiotic management for Clostridium difficile infection. J Gastrointest Infect 2016; 6 (1):3-11.

DOI: 10.5005/jp-jogi-6-1-3

License: CC BY-SA 4.0

Published Online: 01-05-2015

Copyright Statement:  Copyright © 2016; The Author(s).


Clostridium difficile infection (CDI) is a key cause of diarrheal illness due to outbreaks by the hypervirulent C. difficile NAP1/027 strain. The mainstay and time-honored antibiotic therapies for the management of CDI apart from killing C. difficile, also disturbs the standard healthy gut flora leading to dysbiosis. Mismanagement of antibiotics has led to a widespread increase in antibiotic resistance which has jeopardized the efficacy of antibiotics. This article has shed some light on the present-day vista of non-antibiotic approaches to combat CDI which include bacteriotherapy (fecal microbiota transplant, probiotics, non-toxigenic C. difficile spores), immunoglobulin therapy (monoclonal antibodies, polyclonal antibodies, bovine antibodies, whey protein concentrate, colostrum, C. difficile vaccine), photodynamic therapy and other miscellaneous therapies like the use of adsorbents, prebiotics and corticosteroids.

PDF Share
  1. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758-64.
  2. Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487- 99.
  3. Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag. 2008;4:949-64.
  4. Delmee M, Buts JP: Clostridium difficile-associated diarrhoea in children. In: Buts JP, Sokal EM, editors. Management of digestive and liver disorders in infants and children. Elsevier Science Publishers. 1993;371:9.
  5. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2386-8.
  6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-7.
  7. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis. 2012;54:568-74.
  8. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995.
  9. Schubert AM, Sinani H, Schloss PD. Antibiotic induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio. 2015;6(4):e00974.
  10. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'Re-POOPulating' the gut. Microbiome. 2013;1:3.
  11. Enache-Angoulvant A, Hemnnequin C. Invasive Saccharmyces infection: a comprehensive review. Clin Infect Dis. 2005;41:1559- 68.
  12. Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol. 2016;30:111-8.
  13. Park J, Floch MH. Prebiotics, probiotics and dietary fiber in gastrointestinal diseases. Gastroenterol Clin North Am. 2007;36:47-63.
  14. Lewis S, Burmeister S, Brazier J. Effect of prebiotic oligofructose on relapse of Clostridium difficile associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005;3:442-8.
  15. Rea MC, Sit CS, Clayton E, O'Connor PM, Whittal RM, Zheng J et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci USA. 2010;107:9352-7.
  16. Rea MC, Alemayehu D, Casey PG, O'Connor PM, Lawlor PG, Walsh M et al. Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract. Microbiol. 2014;160:439-45.
  17. Gebhart D, Lok S, Clare S, Tomas M, Stares M, Scholl D. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. MBio. 2015;6: pii:e02368-14.
  18. Rineh A, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR. Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther. 2014;12:131-50.
  19. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854-9.
  20. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap. Adv. Gastroenterol. 2012;5:403-20.
  21. Kelly C, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145-9.
  22. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-9.
  23. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994-1002.
  24. de Castro CG Jr, Ganc, AJ, Ganc, RL Petrolli MS and Hamerschlack N. Fecal microbiota transplant after hematopietic SCT: report of a successful case. Nature. 2015;50:145.
  25. Ganc AJ, Ganc RL. Fecal microbiota transplantation, by means of push enteroscopy. A novel endoscopic technique, for the treatment of chronic diarrhea associated with Clostridium difficile – a pilot study. Gastrointest Endosc. 2014;79:487-8.
  26. Asonuma K, Kuroki Y, Ino S, Hanamura S, Takano Y, Yamamura E et al. Severe refractory Clostridium difficile infection with good response to fecal microbiota transplantation: a case report. Nihon Shokakibyo Gakkai Zasshi. 2016;113:55-62.
  27. Nood EV, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal E G, de Vos WM et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013; 368:407-15.
  28. Mattila E, Anttila VJ, Broas M, Marttila H, Poukka P, Kuusisto K et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis. 2008;40:702-8.
  29. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012;172:191-3.
  30. Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. Nature. 2014; 506:290-1.
  31. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile Colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36: 580-5.
  32. Allegretti JR and Matthew J Hamilton. Restoring the gut microbiome for the treatment of inflammatory bowel diseases. World J Gastroenterol. 2014;20:3468-74.
  33. Clabots CR, Johnson S, Bettin KM, Mathie PA, Mulligan ME, Schaberg DR et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J. Clin. Microbiol. 1993;31:1870-5.
  34. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186:1781-9.
  35. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719-27.
  36. Villano S A, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding D N. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother. 2012;56:5224-9.
  37. Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2016;13:150-60.
  38. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-93.
  39. Kunimoto D, Thomson AB. Recurrent Clostridium difficileassociated colitis responding to cholestyramine. Digestion. 1986;33:225-8.
  40. Moncino MD, Falletta JM. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Am J Pediatr Hematol Oncol. 1992;14:361-4.
  41. Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J. 2004;87: 534-9.
  42. Barker RH, Dagher R, Davidson DM, Marquis JK. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther. 2006;24:1525-34.
  43. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G et al. Tolevamer Study Investigator Group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficileassociated diarrhea. Clin Infect Dis. 2006;43:411-20.
  44. Balagopal A, Sears CL. Clostridium difficile: new therapeutic options. Curr Opin Pharmacol. 2007;7:455-8.
  45. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother. 2001;45:2340-7.
  46. de Gunzburg J, Ducher A, Modess C, Wegner D, Oswald S, Dressman J et al. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects. J Clin Pharmacol. 2015;55:10-6.
  47. de Gunzburg J, Ghozlane A, Ducher A, Duva X, Ruppé E, PharmD et al. DAV132, an adsorbent-based product, protects the gut microbiome and prevents Clostridium difficile Infections during Moxifloxacin Treatments. ID Week 2015; poster 129-760.
  48. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197-205.
  49. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D et al. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Lasers Surg. Med. 2006;38:468-81.
  50. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 2006;74:6339-47.
  51. Hernandez LD, Racine F, Xiao L, DiNunzio E, Hairston N, Sheth PR et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015;59:1052-60.
  52. Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822-31.
  53. Wilcox M, Gerding D, Poxton I, Kelly C, Nathan R, Cornely O et al. Bezlotoxumab (BEZ) Alone and With Actoxumab (ACT) for Prevention of Recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics: Integrated results of 2 Phase 3 studies (MODIFY I and MODIFY II). ID Week press conferences. 2015
  54. /Pivotal-Phase-3-Studies-Bezlotoxumab-Merck%E2%80%99s- Investigational
  55. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 2000; 342:390-7.
  56. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 2008; 46 Suppl 1:S43-9.
  57. Shone C, Landon J. Antibodies to Clostridium difficile toxins (WO2010094970 A1). 2010:53.
  58. Wilcox MH. Descriptive study of intravenus immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 2004;53:882-4.
  59. Leung DY, Kelly CP, Bogunlewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118:633-7.
  60. Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hospital Med. 2010;5:E1-9.
  61. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile associated disease in a hamster model of infection. Infect Immun. 1998;66:2018-25.
  62. Mulvey GL, Dingle TC, Fang L, Strecker J, Armstrong GD. Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection. J Med Microbiol. 2011;60:1181-7.
  63. Van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P et al. Bovine antibody enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhea: preclinical and preliminary clinical data. J Med Microbiol. 2005;54:197-205.
  64. Young KW, Munro IC, Taylor SL, Veldkamp P, van Dissel JT. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol. 2007;47:317-26.
  65. Kim K, Pickering LK, DuPont HL, Sullivan N and Wilkins T. In vitro and in vivo activity of human colostrum and milk against purified toxins A and B of Clostridium difficile. J Infect Dis. 1984;150:57-62.
  66. Dallas SD, Rolfe RD. Binding of Clostridium difficile toxin A to human milk secretory component. J Med Microbiol. 1998;47:879- 88.
  67. Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother. 1997;41:236-41.
  68. Steele J, Sponseller J, Schmidt D, Cohen O, Tzipori S. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immun other. 2013;9:1565-8.
  69. Artiushin S, Timoney JF, Fettinger M, Fallon L, Rathgeber R. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding. Equine Vet J. 2013;45:476-80.
  70. Naaber P, Lehto E, Salminen S, Mikelsaar M. Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol Med Microbiol. 1996;14:205-9.
  71. Sponseller JK, Steele JA, Schmidt DJ, Kim HB, Beamer G, Sun X, Tzipori S. Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis. 2015;211:1334- 41.
  72. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxinA. Infect Immun. 2003;71:1608-10.
  73. Souigioltzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C et al. Clostridium difficile toxoid vaccine in recurrent C. difficileassociated diarrhea. Gastroenterology. 2005;128:764-70.
  74. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. ADNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine. 2009;27:3598-604.
  75. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Mouse relapse model of Clostridium difficile infection. Infect Immun. 2011;79:2856-64.
  76. Huang JH, Wu CW, Lien SP, Leng CH, Hsiao KN, Liu SJ et al. Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci. 2015;22:65.
  77. Calin MA, Parasca SV. Light sources for photodynamic inactivation of bacteria. Lasers Med Sci. 2009; 24:453-60.
  78. St Denis TG, Dai T, Izikson L, Astrakas C, Anderson RR, Hamblin MRet al. All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease. Virulence. 2011; 2:509-20.
  79. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004; 3:436-50.
  80. Ergaieg K, Chevanne M, Cillard J, Seux R. Involvement of both Type I and Type II mechanisms in Gram-positive and Gramnegative bacteria photosensitization by a meso-substituted cationic porphyrin. Sol Energy. 2008; 82:1107-17.
  81. Butt MA, de Sordi L, Yahioglu G, Moose C, Battah S, Stamati I et al. PTH-008 Photodynamic Antimicrobial Chemotherapy (PACT) selectively kills Clostridium difficile over colon cells and is effective against 5 hypervirulent strains of the pathogen. Gut. 2013;62:A215.
  82. de Sordi L, Butt MA, Pye H, Kohoutova D, Mosse CA, Yahioglu G et al. Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile. PLoS One. 2015;10(8):e0135039.
  83. Cavagnaro C, Berezin S, Medow MS. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch Dis Child. 2003;88:342-4.
  84. Urayama S, Chang EB. Mechanisms and treatment of diarrhea in inflammatory bowel diseases. Inflamm Bowel Dis. 1997;3:114-31.
  85. Chang TW, Gorbach SL, Bartlett JG. Inhibition of binding of Clostridium difficile toxin by steroids. J Infect Dis. 1980;142:113.
  86. Wojciechowski AL, Parameswaran GI, Mattappallil A, Mergenhagen KA. Corticosteroid use is associated with a reduced incidence of Clostridium difficile-associated diarrhea: a retrospective cohort study. Anaerobe. 2014;30:27-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.